Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural)  or those provided by our clients, compound management, hit identification and hit validation.  Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures. 

Keensight Capital to acquire a majority stake in Axxam, a leading European partner research organization in life sciences

Keensight Capital has reached an agreement to invest alongside management in Axxam.

Axxam has obtained a license from iPS Academia Japan to use iPS cells and iPS-derived cells for drug discovery services

With the aim to offer drug discovery services using human induced pluripotent stem cells (iPS cells) and iPS-derived cells, Axxam has entered into a license agreement with iPS Academia Japan.

Data analysis and compound handling

22 February 2022
16.00 CET

Axxam S.p.A. announces the merger of its two German subsidiaries into Axxam GmbH

The two German subsidiaries of Axxam S.p.A., Hit Discovery Constance GmbH and IMAX Discovery GmbH, merged into Axxam GmbH

Electrophysiology: ion channel drug discovery

Available to view
in December 2021

Subscribe to Our Newsletter

Follow us on